Y Intercept Hong Kong Ltd Takes $382,000 Position in Haemonetics Co. (NYSE:HAE)

Y Intercept Hong Kong Ltd bought a new stake in shares of Haemonetics Co. (NYSE:HAE) in the third quarter, Holdings Channel reports. The fund bought 4,752 shares of the medical instruments supplier’s stock, valued at approximately $382,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of Haemonetics in the second quarter worth about $39,000. Daiwa Securities Group Inc. acquired a new position in Haemonetics in the second quarter valued at approximately $82,000. Canada Pension Plan Investment Board acquired a new position in Haemonetics in the second quarter valued at approximately $83,000. Nisa Investment Advisors LLC boosted its position in Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $140,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Bank of America assumed coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. BTIG Research assumed coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. started coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $82.20 on Tuesday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The business’s 50 day moving average price is $81.16 and its 200 day moving average price is $81.48. The company has a market cap of $4.13 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 1.29 and a beta of 0.38. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.99 EPS. On average, research analysts predict that Haemonetics Co. will post 4.59 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.